kabutan

ASKA Pharma, Ordinary Profit Forecast for the Fiscal Year Revised Downward by 12%

Tue Nov 4, 2025 4:10 pm JST Earnings

4886 ASKA Pharmaceutical Holdings Co.,Ltd. 【J-GAAP】

Earnings Report

ASKA Pharmaceutical Holdings Co.,Ltd. <4886> [TSE Prime] announced its financial results after the market closed on November 4th (16:10). The consolidated ordinary profit for the cumulative second quarter of the fiscal year ending March 2026 (April to September) decreased 19.7% from the same period last year to 2.66 billion yen.

In addition, the full-year forecast for consolidated ordinary profit has decreased 11.8%, from the previous forecast of 6.80 billion yen to 6.00 billion yen (compared to 5.10 billion yen in the previous period), leading to a reduction in the profit growth rate from 33.2% to 17.5%.

Based on the first-half performance announced by the company and the full-year plan, our calculation indicates that the consolidated ordinary profit for the October to March period (second half) is expected to expand 86.1% from the same period last year, reaching 3.34 billion yen.

In the most recent three-month period, from July to September (2Q), the consolidated ordinary profit dropped to 1.04 billion yen, a 30.6% decrease compared to the same period last year. The operating profit margin drastically worsened from 9.9% in the same period last year to 6.6%.

Kabutan News

Actual Results

Accumulated Results 2nd Quarter
Fiscal Year Revenue Operating Profit Ordinary Profit Net Profit Adj. EPS Progress Rate vs. First Half Announce Accounting Standards
Apr - Sep, 2023 31,648 3,055 3,096 4,129 145.9 47.5 Nov 6, 2023 J-GAAP
Apr - Sep, 2024 32,371 3,345 3,312 2,560 90.4 64.9 Nov 5, 2024 J-GAAP
Apr - Sep, 2025 35,253 2,649 2,660 2,226 78.5 44.3 Nov 4, 2025 J-GAAP
YoY +8.9% -20.8% -19.7% -13.0% -13.1%

First Half Results vs. Previous Guidance

Fiscal Year Revenue Operating Profit Ordinary Profit Net Profit Adj. EPS Adj. Dividend Announce Accounting Standards
Apr - Sep, 2025 Guidance ー ー ー ー － 27 May 12, 2025 J-GAAP
Apr - Sep, 2025 Results 35,253 2,649 2,660 2,226 78.5 27 Nov 4, 2025 J-GAAP
Revision Rate － － － － －

Guidance Update

Full Year Update

Fiscal Year Revenue Operating Profit Ordinary Profit Net Profit Adj. EPS Adj. Dividend Announce Accounting Standards
Mar, 2026 Prev 75,000 6,800 6,800 5,200 183.1 55 May 12, 2025 J-GAAP
Mar, 2026 New 71,000 6,000 6,000 5,000 176.1 55 Nov 4, 2025 J-GAAP
Revision Rate -5.3% -11.8% -11.8% -3.8% -3.8%

Current Period Guidance

Second Half Results

Fiscal Year Revenue Operating Profit Ordinary Profit Net Profit Adj. EPS Adj. Dividend Announce Accounting Standards
Oct - Mar, 2024 31,768 1,986 1,795 2,541 89.6 30 May 12, 2025 J-GAAP
Oct - Mar, 2025 Guidance 35,747 3,351 3,340 2,774 97.7 28 Nov 4, 2025 J-GAAP
YoY +12.5% +68.7% +86.1% +9.2% +9.0%

Current Period Guidance

Fiscal Year Revenue Operating Profit Ordinary Profit Net Profit Adj. EPS Adj. Dividend Announce Accounting Standards
Mar, 2024 62,843 6,500 6,522 7,545 266.5 40 May 10, 2024 J-GAAP
Mar, 2025 64,139 5,331 5,107 5,101 180.0 55 May 12, 2025 J-GAAP
Mar, 2026 Guidance 71,000 6,000 6,000 5,000 176.1 55 Nov 4, 2025 J-GAAP
YoY +10.7% +12.5% +17.5% -2.0% -2.2%

Quarterly Results

Fiscal Year Revenue Operating Profit Ordinary Profit Net Profit Adj. EPS Operating Profit Margin Announce Accounting Standards
Jul - Sep, 2024 16,019 1,587 1,499 1,287 45.4 9.9 Nov 5, 2024 J-GAAP
Oct - Dec, 2024 17,555 2,150 2,134 1,538 54.3 12.2 Feb 3, 2025 J-GAAP
Jan - Mar, 2025 14,213 -164 -339 1,003 35.4 -1.2 May 12, 2025 J-GAAP
Apr - Jun, 2025 17,641 1,479 1,620 1,244 43.9 8.4 Aug 4, 2025 J-GAAP
Jul - Sep, 2025 17,612 1,170 1,040 982 34.6 6.6 Nov 4, 2025 J-GAAP
YoY +9.9% -26.3% -30.6% -23.7% -23.8%

Related Articles